 Confidential: Contains Proprietary Information  
                                                              D009530  
                                                        Rev03  
                                     
 
 
 
Prospective Registry of Outcomes with Penile Prostheses for 
Erectile Restoration (PROPPER) ER1005 
 
 
BSC Study U0552 (also known as AMS Study ER1005)*  Version #: 3 
Version Date: March  17, 201 6 
 
Version Number                Date of Version  
1 (Initial Relea se)         March 16, 2011  
2 (Amended)      May 12, 201 4 
3 (Amended)      March 17, 201 6 
  
 
Registry Sponsor  
[LOCATION_011] Scientific Corporation (BSC) 
[ADDRESS_278038] Phone:  [PHONE_4852]       
E-mail: Meaghan.Wil [EMAIL_4511] 
 
Ethical Conduct 
This registry will be conducted in compliance with this document, the principles of Good Clinica l Practices 
and other applicable regulatory requirements  or standards . 
 
Confidential Information  
No use of disclosure of this document outside [LOCATION_011] Scientific Corporation is permitted without prior 
written authorization from American Medical Systems.  
 
 
*AMS was acquired by [CONTACT_230849] 2015. Due to the fact that the PROPPER Registry was ongoing at 
time of acquisition, study documents may refer to the study as BSC Study U0552 and/or AMS Study ER1005.  
 
     
 
   
BSC Study:  U0552 V3 March 17, 2016  Protocol Signature [CONTACT_230880] (PROPPER) ER1005 
BSC Study #:  ER1005  
Version #: 3 
Version Date: March 17, 201 6 
 
Version Number                Date of Version  
1 (Initial Release)         March 16, 2011 
2 (Amended)               May 12, 2014  
3 (Amended)               March 17, [ADDRESS_278039]/Ethics Committee (IRB/EC), and any other applicable regulat ory requirements or standards. I will provide 
copi[INVESTIGATOR_230835] /EC.  I will ensure they are fully informed regarding the conduct 
of the study according to this protocol and  applicable laws  and regulatory requirements.  
 
_____________________    Clinical Site Name   
 ____________________________________                ________________ Site Principal Investigator [INVESTIGATOR_230836]  
 ____________________________________ Site Principal Investigator [INVESTIGATOR_230837]: 
[LOCATION_011] Scientific Corporation  (BSC ) 
[ADDRESS_278040] 
Minnetonka, MN [ZIP_CODE], [LOCATION_003] 
Attn:  Curtis Blackwell , Clinical Urology 
Phone:  [PHONE_4853]   Fax:  [PHONE_4854]  
 
 
  
 
 
 
   
BSC Study:  U0552 V3 March 17, 2016   
Table of Contents   
PROTOCOL SIGNATURE P AGE  ................................................................................................................ 2 
1 PROPPER REGISTRY STU DY SYNOPSIS ....................................................................................... 1 
2 BACKGROUND AND REGIS TRY RATIONALE .............................................................................. 12 
2.1 BACKGROUND  ..................................................................................................................................... 12 
2.2 REGISTRY DESIGN RATIONALE  ................................................................................................................ 13 
2.3 DEVICE  DESCRIPTION  ....................................................................................................................... 14 
2.4 DEVICE  ACCOUNTABILITY  ................................................................................................................ 14 
3 REGISTRY OBJECTIVES  ................................................................................................................ 15 
3.1 MAIN  OBJECTIVE  ................................................................................................................................. 15 
4 REGISTRY DESIGN SUMM ARY...................................................................................................... 15 
5 PATIENT ELIGIBILITY  ..................................................................................................................... 16 
5.1 INCLUSION  CRITERIA  ......................................................................................................................... 16 
5.2 EXCLUSION  CRITERIA  ........................................................................................................................ 16 
6 PATIENT ENROLLMENT  ................................................................................................................. 16 
7 DATA COLLECTIO N ........................................................................................................................ 16 
7.1 DEVICE  USE  AND  SATISFACTION  QUESTIONS ........................................................................... 17 
7.2 DEPRESSION  HISTORY  QUESTIONS  ............................................................................................. 18 
7.3 PATIENT  QUESTIONNAIRES  ............................................................................................................. 18 
7.3.1  International Index of Erectile Function- 5 / Sexual Health Inventory for Men (IIEF -5/SHIM)  19 
7.3.2  EHS Erection Hardness Questionnaire  ................................................................................. 19 
7.3.3  SF-12 Health- related Quality of Life (HRQOL) Questionnaire  .............................................. 19 
7.3.4  American Urological Association – Symptom Index (AUA- SI) .............................................. 19 
7.3.5  UCLA -Prostate Cancer Index (UCLA -PCI) Questionnaire  .................................................... 20 
7.4 SAFETY  ASSESSMENTS .................................................................................................................... 20 
7.4.1  CLINICAL STUDY EVENTS  .................................................................................................. 20 
7.4.2  DEVICE COMPLAINT REPORTING ..................................................................................... 21 
7.4.3  SAFETY REPORTING  .......................................................................................................... 21 
8 STATISTICAL METHODS AND DATA ANALYSIS  ......................................................................... 24 
8.1 SAMPLE  SIZE  ........................................................................................................................................ 24 
8.2 SAFETY  OBJECTIVES  ......................................................................................................................... 24 
8.3 EFFECTIVENESS  OBJECTIVES  ........................................................................................................ 25 
8.3.1  EFFECTIVENESS OBJECTIVE 1 – DEVICE USE AND SATISFACTION  ........................... 25 
8.3.2  EFFECTIVENESS OBJECTIVE 2 – IIEF-5/SHIM QUESTIONNAIRES  ............................... 26 
8.3.3  EFFECTIVENESS OBJECTIVE 3 – EHS QUESTIONNAIRES  ............................................ 27 
8.3.4  EFFECTIVENESS OBJECTIVE 4 – SF-12 HRQOL QUESTIONNAI RES............................ 28 
8.3.5  EFFECTIVENESS OBJECTIVE 5 – AUA- SI/IPSS QUESTIONNAIRES  .............................. 28 
8.3.6  EFFECTIVENSS OBJECTIVE 6 – UCLA -PCI QUESTIONNAIRES  ..................................... 29 
8.3.7  ADDITIONAL EFFECTIVNESS OBJEC TIVES ..................................................................... 30 
8.4 ADDITIONAL  DATA  ANALYSIS  .......................................................................................................... 31 
8.4.1  SUBGROUP ANALYSIS  ....................................................................................................... 31 
8.4.2  PHYSICIAN DATA  ................................................................................................................ 31 
8.4.3  BASELINE/ PRE- OPERATIVE DATA  ................................................................................... 31 
8.5 IMPLANTATION  DATA ......................................................................................................................... 33 
9 PROTOCOL DEVIATIONS  ............................................................................................................... 34 
10 DATA ANALYSIS  ............................................................................................................................. 34 
11 DATA SECURITY  ............................................................................................................................. 35 
12 DATA QUALITY ASSURA NCE  ........................................................................................................ 35 
 
   
BSC Study:  U0552 V3 March 17, [ADDRESS_278041] (IRB)/ETHICS COMMITTEE (EC) REVIEW  ........................... 35 
15 INFORMED CONSENT AND PATIENT PRIVACY  .......................................................................... 36 
16 STUDY RECORDS AND RE PORTS  ................................................................................................ 36 
16.1  PHYSICIAN  REPORTS  ........................................................................................................................ 37 
16.2  BSC  REPORTS  ...................................................................................................................................... 38 
17 PHYSICIAN NON- COMPLIANCE AND STUDY  TERMINATION  .................................................... 38 
18 PUBLICATION PLAN  ....................................................................................................................... 38 
19 REFERENCES  .................................................................................................................................. 40 
APPENDIX 1 - QUESTIONNAIRES  ........................................................................................................... 47 
International Index of Erectile Function- 5 / Sexual Health Inventory for Men (IIEF -5/SHIM) ............. 47 
EHS Erection Hardness Questionnaire  .............................................................................................. 48 
SF-12 Health- related Quality of Life (HRQOL) Questionnaire  ........................................................... 48 
American Urological Association – Symptom Index (AUA- SI) ........................................................... 50 
UCLA -Prostate Cancer Index (UCLA -PCI) Questionnaire  ................................................................. 52 
 
Table of Tables  
Table 1: Electronic data collection schedule  ................................................................... 9 
Table 2: Description and Submission Requirements of Physician Reports  ................... 37 
Table 3: Description and Submission Requirements of BSC Reports  ........................... 38 
 
Table of Figures  
Figure 1: Study Flow Diagram  ....................................................................................... 11 
D009530  
Rev02 
 
BSC Study: U0552-181050 March 1 7, 2016 Page 1 of 55 
 1 PROPPER REGISTRY STUDY SYNOPSIS  
 
Sponsor : [LOCATION_011] Scientific Corporation  (BSC)  
Protocol Title (BSC  
Study Number) : Prospective Registry of Outcomes with Penile Prosthes es for 
Erectile Restoration (PROPPER)  (ER1005)  
Clinical Phase and  
Regulator y Status  Post-Market Registry  
Study Sites:  Up to 16 sites throughout the [LOCATION_003] and Canada  
 
Principal Investigators:   
Anthony J. Bella, MD, FRCSC  
University of Ottawa Ontario, Ontario, Canada  
 
Rafael E. Carrion, MD  
University of South [LOCATION_012], Tampa, FL, U SA 
  Brian S. Christine, MD  
Urology Centers of Alabama, Birmingham, AL, [LOCATION_003]  
  
Gerard D. Henry, MD  
Regional Urology; Shreveport, LA, [LOCATION_003]  
 
Additional investigators are expected.  The names and 
addresses of all participating Princip al Investigators will be 
maintained in a separate document.    
 
Objectives:  To understand “real -world” outcomes  for men implanted with 
BSC penile prostheses,  including the following: 
 Safety  
 Durability  
 Patient  satisfaction  
 Effectiveness/Quality of Life  
 
Study Design:  Prospective, multi -center, post -market, observational registry, 
up to 5 year follow -up 
Planned Sample Size:  Approximately 500 -1500  
Inclusion Criteria:  Men diagnosed with erectile dysfunction (ED) for whom a 
BSC penile prosthesis is recommended by [CONTACT_230850].  Potentially eligible men should also 
meet the following inclusion criteria for study enrollment:  
 Willing and able to provide written informed consent prior to 
enrollment (if applicable).  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 2 of 55  Willing to be seen or contact[CONTACT_230851] 2 questions related to treatment 
satisfaction and device use 1 year following implantation of 
an BSC penile prosthesis  
 
Exclusion Criteria:  Men who are deemed by [CONTACT_230852] a penile implant are excluded from eligibility .  
 
Device Description(s):  Men to be enrolled and followed in this study include those 
implanted with one of the following  marketed BSC penile 
prostheses:  
 3-pi[INVESTIGATOR_230838] (e.g., AMS 700®)  
 2-pi[INVESTIGATOR_230838] (e.g., AMS Ambicor®)  
 Malleable or concealable penile prosthesis (e.g., 
Spectra ™) 
 
Implantation 
Description:  BSC recommends that all devices are implanted according 
to the device specific Instruction for Use (IFU) and/or 
Operating Room (OR) manual and the site or investigator’s 
standard of care.  
Concomitant Surgical 
Procedures:  Concomitant urological procedures are allowed and will be 
captured; however, outcomes data on these procedures will not be collected , unless an AMS  800 artificial urinary 
sphincter or AdVance male sling is implanted concomitantly with the BSC penile prostheses . Optional questionnaires will 
be available to use for assessment . 
Implantation Success 
Measures:  Success will be measured post -operatively by [CONTACT_230853].  Any 
reported int ra-operative and post -treatment  complications 
will be collected in the registry database.  
Event Schedule:  Patient  data will be collected from the baseline/pre -operative 
visit, the impla ntation procedure, and follow -up evaluations 
which will occur according to each physician’s standard of care, up to [ADDRESS_278042] -implantation . A 1-year follow -up 
evaluation will be required, and a 2- year follow -up evaluation 
will be strongly encouraged.  
Duration of Study:  1-2 year enrollment period  
Up to 5 year patient  follow -up 
Measurements:  The registry database will include required measures for all 
participating investigators  to complete and optional 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 3 of 55 measures  (listed below in italics) for investigato rs to 
complete if they coincide with their standard of care.  
 
Each investigator will be asked basic practice information 
including:  
• Practice type (private, academic)  
• Main setting for procedures (Hospi[INVESTIGATOR_230839])  
• Do you provide standard device cycling instructions to 
patient s receiving IPPs? If yes, please describe your 
protocol  
 
Data for each patient  for whom a BSC penile implant is 
recommended will be entered into the registry database at 
baseline/procedure  and at post -implant follow -ups to occur 
at a minimum 1 year after implantation, and through up to 5 
years after implantation.  
 The baseline/pre- operative data will include:  
• Age 
• Race/Ethnicity  
• Primary etiology of ED  
o Organic  
 Diabetes  
 Cardiovascular disease 
 Neurologic disorder  
 Peyronie’s disease  
 Other  organic (specify)  
o Acute 
 Radical prostatectomy (RP) (robotic, open or laparoscopic)  
 Radical pelvic surgery (other than RP)  
 Pelvic radiation therapy  
 Pelvic trauma or injury  
 Spi[INVESTIGATOR_1828]  
 Venous Leak  
 Priapi[INVESTIGATOR_8801]  
 Other acute (specify)  
• Relevant concomitant medical conditions and concomitant medications that might impact ED (premature or rapid ejaculation/PE, climacturia, cardiovascular disease, diabetes, Peyronie’s disease, stress urinary incontinence/SUI, steroid use, anticoagulant use, anti -depressant use,  venous leak,  
and Other, please specify) – with the following sub -
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 4 of 55 assessments if SUI checked:  
o Etiology of incontinence (radical 
prostatectomy, pelvic irradiation, and other – 
please specify)  
o Previous treatment(s) for incontinence (behavior modification, pel vic floor muscle 
training, transobturator male sling - specify 
model and implant date, artificial urinary sphincter/AUS – specify implant model date, 
other - specify)  
o Number of pads used daily  
o Pad weight (24- hour test)  
o Urodynamics:  Post -void residual (PV R) 
volume (ml), maximum flow rate (ml/sec), any detrusor overactivity (DO) or detruser sphincter dyssynergia (DSD)  
o Cystoscopy findings (bladder neck contracture, other – specify) 
• Pre-op flaccid penile length (measured from 
suprapubic fat pad to tip)  
• Pre-op stretched penile length (measure from 
suprapubic fat pad to tip)  
• Pre-op flaccid girth (circumference measured 1cm 
proximal to the proximal end of the corona)  
• Duration of ED (years or months)  
• Previous ED Treatments [ PDE-5 inhibitor s (PDE -5s), 
vacuum erect ion device (VED), intracavernosal 
injection (ICI), Combination therapi[INVESTIGATOR_014], previous/failed penile implants), other, specify ] 
• Patient  query - any office visits in past year for 
treatment of depression Y/N  
o If Yes: approximately how many visits  
o If Yes: taking any depression medication  
• Was VED and/or penile traction therapy prescribed 
pre-operatively? ( Y/N) 
o If Yes:  specify Duration (weeks) and Frequency (times/day)  
• Baseline effectiveness/quality of life assessments  
 Implantation surgery data will include: 
• Date of procedure  
• Original (virgin) , revision , salvage or replacement  
implant  
o If revision  or salvage , washout (Y/N)  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 5 of 55 • Surgical approach (Penoscrotal (PS), Infrapubic (IP), 
Subcoronal (SC) or “Other, please specify”)  
• Implant model type: 
o Spectra™ Concealable Penile Prosthesis  
 Cylinder diameter (9.5, 12, 14 mm)  
 Cylinder length (12, 16, 20 cm)  
 Total number of RTEs per cylinder (0, 1, 
2) 
 Total length of RTEs per cylinder (specify: 0.5 to 7.5 cm)  
o AMS Ambicor
® Penile Prosthesis (2- pi[INVESTIGATOR_230840])  
 Cylinder diameter  (12.5, 14, 15.5 mm)  
 Cylinder length (14, 16, 18, 20, 22 cm)  
 Total number of RTEs per cylinder (0, 1, 2, 3, 4)  
 Total length of RTEs per cylinder (specify: 0.5 to 6.5 cm)  
o AMS 700
® Penile Prosthesis (3– pi[INVESTIGATOR_230840])  
 InhibiZone®-impregnated (Y/N)  
 Cylinde r type (CX, LGX, CXR, Ultrex, 
CXM)  
 Cylinder length (10, 12, 14, 15, 16, 18, 21, 24  cm) 
 Total number of RTEs per cylinder (0, 1, 2, 3, 4)  
 Total length of RTEs per cylinder (specify: 0.5 to 7.5 cm)  
 Pump type (MS Pump, Tactile pump, Inflate/Deflate)  
 Preconnec t (Y/N)  
 Reservoir (Spherical 65 ml, Spherical 100 ml, Conceal 100 ml)  
 Reservoir placement (space of Retzius, Sub-muscular, Sub- Scarpa’s fascia, 
other – specify) 
 Reservoir separate incision (Y/N)  
• Drain (Y/N)  
o If Yes, Type  
• Dressing  
o None, compression/mummy wrap, non-compressive dressing  
• Concurrent procedures (Y/N)  
o If Yes , specify procedure(s):  ventral 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278043]/testicular procedure, A MS 800  (single or 
multiple incision ), sling ( specify  sling type and 
single or multiple incision) , other - specify  
• Significant corporal fibrosis or scarring noted (Y/N)  
• C urvature correction procedure(s) (e.g., for 
Peyronie’s Disease) (Y/N)  
o If Yes: Initial intraoperative curvature 
measurement (angle of curvature with inflated 
device using a goniometer or protractor)  
o If Yes: Correction technique (Wilson/Delk remodeling, tunical incision, incision and grafting, or plication)  
o Curvature measurement after correction  
o Second correction? If Yes, same set of 
ques tions as above.   
• Patient  status post -op: Admitted/inpatient/≥24 hours  
or same day discharge/outpatient/<24 hours   
o If admitted/inpatient/≥24 hours is chosen, include: number of days in the hospi[INVESTIGATOR_307]  
• Length of procedure (measured from time of first incision t o time of closure)  
• Intra-operative penile length measurement with 
device inflated (measured from suprapubic fat pad to tip) 
• Intra-op penile girth measurement with device inflated 
(circumference measured 1cm proximal to the proximal end of the corona)  
• Intra-op stretched penile length measurement with 
device deflated (measured from suprapubic fat pad to tip) 
• Foley in place at discharge? (Y/N)  
 Follow -up is required [ADDRESS_278044] -operatively. Additional 
follow -ups will be determined per the physician’s standard 
practice up to 5 years.  Follow -up data will include:  
• Query for any device related complications and their 
outcomes  by [CONTACT_230854] (Y/N)    
• Patient s will be asked:  
o How satisfied they are with the device(s) 
(using a 5 -point scale)  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 7 of 55 o If they are using the device (Y/N)  
 If yes, how often they are using the 
device (less than once per month or more than once per month)  
o  How many times per month? 
 If no, why aren’t you using the device 
(loss of partner, partner disinterest, device problem, device dissatisfaction, health decline, other – describe, other 
device use reason).  
 If yes, and not using the device as often as desired, or if dissatisfied with t he 
device, indicate why ((loss of partner, partner disinterest, device problem, device dissatisfaction, health decline, other – describe, other device use 
reason).  
• Number of pads used daily (if incontinence indicated pre-operatively)  
• Pad weight (24- hour test) (if incontinence indicated 
pre-operatively)  
• Penile length measurement with device fully inflated 
(measured from suprapubic fat pad to tip)  
• Penile girth measurement with device fully inflated 
(circumference measured 1cm proximal to the proximal end of the corona)  
• Stretched penile length measurement with device deflated (measured from suprapubic fat pad to tip)  
• Patient query - any office visits in past year for 
treatment of depression Y/N  
o If Yes: approximately how many visits  
o If Yes: taking any depression medication  
 
• Effectiveness/quality of life assessments  
 
 
Effectiveness 
Assessments:  Patient questionnaires to measure effectiveness will be 
optional at baseline and at all follow -up visits . Included are 
the following validated, patient -reported outcome 
questionnaires:  
Strongly recommended for all:  
• IIEF-5/SHIM erectile function questionnaire  
• EHS erection hardness questionnaire  
• SF-12 health -related quality of life questionnaire  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278045] -prostatectomy 
ED or incontinence:  
• AUA-SI/IPSS urinary symptom questionnaire  
• UCLA -PCI urinary, sexual and bowel function and 
bother questionnaire  
Safety/Device 
Malfunction 
Assessments:  Any reported intra -operative or post -operative device or 
surgery related complications will be recorded throughout 
study follow -up (for BSC products only). This information will 
include:  
• Complication  
• Treatment  
• Location of treatment  
• Resolution (Resolved or Continuing)  
Potential device or surgery related complications are 
described in the device specific IFU and  OR manuals.  
Statistical Analyses, 
Including Determination 
of Sample Size:  Up to 1500 patient s with erectile dysfunction (ED) electing to 
receive a BSC penile prosthesis implant will be included in 
this registry.  
 
Analyses of multi -center data for initial  publication(s) may be 
performed after approximately 500 patient s complete 1 year 
follow -up. Additional individual and multi -center data 
analyses may be performed as warranted throughout the study for publication(s).  Analysis for multi -center 
publication(s ) is planned after the study enrollment is 
complete and all the enrolled patient s have completed their 
one-year and five- year follow -up evaluations , consistent with 
each physician’s  standard of care. 
 Continuous variables will be presented as mean +/ - SD; 
ordinal variables will be summarized using median with interquartile ranges; categorical variables will be presented as count and proportion.  
 Kaplan- Meier method will be used to estimate the event rate 
over time by [CONTACT_230855].  
 
For within -patient  change at [ADDRESS_278046] may be 
used for continuous variables and McNemar’s test may be 
used for binary variables when applicable. Mixed effects model or Generalized Estimating Equation model may be 
used to estimate the change from baseline across follow up 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 9 of 55 visits when appropriate.  
 
 The data to be collected in electronic data forms will include the following:  
 
 
Table 1: Electronic data collection schedule  
Data  Baseline/ 
Procedure  Interim 
Follow -Up* 1 Year 
Follow -Up* 2 - 5 Year  
(Annual)  
Follow -Up* 
Date of Informed 
Consent/first data record  R    
Demographics and 
Characteristics  R    
ED History  R    
Depression History  O N/A O O 
Implantation Proc edure 
Details  R    
Device Use and 
Satisfaction  N/A O R SE 
Penile Measurements  O O O O 
Incontinence Data  O O O O 
Patient Questionnaires  SE SE SE SE 
Clinical Study 
Events/Complications  R† R† R† R† 
* The same assessments, evaluations, questionnaires that were completed at baseline should be completed at follow -up 
R = Required, O = Optional, SE = Strongly Encouraged , N/A = Not Applicable . 
† = if applicable  
 
o Demographics and Characteristics – age, race/ethnicity, concomitant medical 
conditions and medicati ons 
o ED History – primary etiology of ED, previous ED treatments  (optional)  
o Depression History – query for any treatment of depression in past year – 
optional at baseline and at annual follow -up 
o Implantation Procedure Details – surgical procedure details an d implant model 
information, patient status post -op 
o Device Use and Satisfaction – query for device use and device satisfaction  
o Penile Measurements – pre-op flaccid and stretched length and girth, intra- op 
inflated penile length and girth and deflated stretched length, and post -operative 
inflated length and girth measurements, by [CONTACT_5936] 
o Incontinence Data –  Daily pad use, pad weight tests, ur odynamics , post-void 
residual (PVR) volume maximum flow rate  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 10 of 55 o Patient Questionnaires – IIEF-5/SHIM erectile functio n questionnaire; EHS 
erection hardness question; SF -12 health- related quality of life questionnaire; 
AUA-SI symptom questionnaire; UCLA -PCI urinary, sexual and bowel function 
and bother questionnaire 
o Clinical study events  – device or procedure related comp lications (adverse 
device effects/events), device malfunctions, revision procedures related to the 
device or implantation procedure  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 11 of 55  
Figure 1: Study Flow Diagram  
Baseline/prosthesis 
implantation data Enrollment
Informed Consent Form and/or 
HIPAA Authorization signed by 
[CONTACT_230856]-up Assessments
Required [ADDRESS_278047] of care 
(approximately yearly up to 5 years)
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 12 of 55  
2 BACKGROUND AND REGISTRY RATIONALE  
2.1 B ACKGROUND  
Erectile dysfunction (ED), or impotence,  is defined as a persistent failure to develop and 
maintain erections sufficient for penetrative sexual intercourse. 1   The total prevalence 
of erectile dysfunction of varying degrees in the [LOCATION_002] is  estimated to be 
approximately 30 million. According to the [LOCATION_005] Male Aging Study, an 
estimated 52% of men over [ADDRESS_278048] on 
sexual function after prostatectomy, even if erectile function is eventually restored.  
10-15  
Erectile dysfunction also occurs in up  to 86% of patients after androgen deprivation 
therapy, as well as after external beam radiation therapy  for prostate cancer . 16-18 
Restoration of the same degree of potency enjoyed prior to radical prostatectomy ( RP) 
occurs only rarely, and older men and those with decreased pre- operative function 
generally recover erections less fully  than pre- potent  and younger  men. Nerve sparing 
surgeries  have increased the recovery of post -prostatectomy  erectile function by 
[CONTACT_3450] 20%  1- 2 years after surgery to over 50% for unilateral and over 75% for 
bilateral nerve sparing procedures performed by [CONTACT_230857]. However, even with early penile rehabilitation using  PDE-5 drug therapy or vacuum erection devices to aid 
in the restoration of function, only approximately 50- 60% of patients will have 
unassisted functional erections restored by [ADDRESS_278049] quality of life and psychosocial status, as sexual health is integral to overall well -being. 
38, 39  
 Although there is a large body of scientific  literature describing outcomes associated 
with penile implants, articles reporting prospectively collected,  validated outcomes in 
large numbers of patients  implanted with modern  BSC penile implant models are 
limited.      
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 13 of 55 2.2 Registry Design Rationale  
The sel ection of specific effectiveness data measurements in this Registry study was 
based on outcomes reported in published literature for a range of current ED treatment 
options, to allow for generalized comparisons between modern, prospective penile prosthesis  outcomes and historical data for a variety of ED  treatments.  
 Current recommendations for ED diagnosis, management and research from 
international evidence- based consensus panels were also consulted to determin e which 
patient -reported outcomes (PROs) are  measured as part of the standard of care for 
clinical evaluation and treatment of ED.
40-43  
 In both clinical practice and research, it has been recommended that  ED severity be 
categorized using the International Index for Erectile Function EF domain (IIE F-EF).  
The IIEF-5 (also identified as the Sexual Health Inventory for Men or SHIM)  is a 
validated and well established erectile function measure comprised of 5 of the 15 IIEF 
items, including  4 of the 6 IIEF -EF questions and one question from the intercourse 
satisfaction domain. 
44-49 A single -item, validated erection hardness scale/score (EHS) is 
also commonly recommended and used . 50- [ADDRESS_278050] -treatment erectile function  and penile rigidi ty in 
many clinical trials of ED pharmacotherapy and devices as well as in clinical practice .   
 For patients with ED due to treatment of prostate cancer, the UCLA Prostate Cancer Index (UCLA -PCI) is a validated 20- item tool for measurement of health -related quality 
of life specific to sexual, urinary, and bowel function and bother ; and has been 
employed in numerous published studies to demonstrate serial improvements or declines in the six domains commonly affected by [CONTACT_230858]. 
49, 54- 58 
Each UCLA -PCI domain scale is scored on a scale of 0– 100 points with higher values 
representing better outcomes. A difference of 5– [ADDRESS_278051] transiently, and is measured in clinical practice and research using pad counts and weights and validated PROs. 
47-48, 60- 63 The American Urological 
Association Symptom Index (AUA -SI) is comprised of 7 of the 8  items of the 
International Prostate Symptom Score (IPSS), and has been widely used to report baseline and post -treatment clinical urinary symptom outcomes. 
56, 64 -67 
 General health- related quality of life ( HRQOL ) has been evaluated in many different 
disease state settings with serial assessments  using the Short Form Health Survey (SF -
12), which is a 12-item adaptation of the RAND 36- Item Health Survey (SF -36) that 
takes only two to three minutes to complete.  T he SF -12 (v2) is a practical, reliable, and 
valid measure of physical and mental health widely used in large population applications.  The SF -12v2 is available in multiple modes of administration and in both 
standard four  week  and acute one  week recall periods. The SF -12 quanti fies HRQOL 
into two composite scores : the Physical Component Summary (PCS) and Mental 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 14 of 55 Component Summary (MCS) scales.   This survey  also quantifies HRQOL into the same  
eight multi -item subscale  domains used in the SF -36 with one or two questions in each 
domain:  physical functioning, emotional well -being, general health, pain, energy, social 
functioning, and role limitations (problems with work or other daily activities ) as a result 
of physical or emotional health.49, 57- 58, 67- [ADDRESS_278052] of care for management of patients with ED before and after implantation of a 
penile prosthesis.  The two, simple, individual questions about device use and 
satisfaction with the device were selected based on this feedback and the published studies using similar single- item assessments, since there is no validated tool available 
at present to measure the outcomes associated with penile implants as a treatment for ED.      
 The required 1- year follow -up time frame was chosen based on a large body of 
literature reporting clinical outcomes of this duration or longer after ED treatment, and the recommendations in the labeling for BSC penile prostheses for evaluating long -term 
device function [AMS 700® with MS Pump Operating Room Manual, 06/10].  The 
overall 5- year follow -up time frame is the minimum duration that is generally considered 
long-term follow -up after penile implantation. 
40  
2.3 DEVICE DESCRIPTION  
Devices included in this registry are the AMS 700 ® Series Inflatable Penile Prosthesis, 
AMS Ambicor® Penile Prosthesis, and the Spectra™ Concealable Penile Prosthesis. 
These devices have been approved for marketing and are manufactured by [CONTACT_230859]  (Marlborough, MA , [LOCATION_003]).  The penile prostheses are intended for  
use in the treatment of chronic, organic, male erectile dysfunction (impotence). These devices are for men who, after appropriate patient history and diagnostic evaluation as well as discussions with the urologist about other alternative treatment methods, are determined to be suitable candidates for implantation surgery.  For specific device descriptions and information about their use and implantation refer to each device’s Instructions for Use (IFU) and Operating Room (OR) Manual.  
 
2.[ADDRESS_278053] been 
approved for marketing, and will be obtained by [CONTACT_230860].  A BSC Patient Information Form (PIF) related t o 
each surgical implant procedure may be completed as per standard practice in addition 
to entering implant data into the study database.  Individual device unit or lot numbers 
will not be tracked or accounted for in this study.  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278054] data prior to and after BSC 
penile prosthesis implantation in order to document and evaluate ‘real -world’ penile 
prosthetic outcomes including safety, durability, patient satisfaction and 
effectiveness/Quality of Life.  
[ADDRESS_278055] data for any concomitantly implanted AMS 8 00 Artificial 
Urinary Sphincters or AdVance slings for the treatment of incontinence.  
 BSC recommends that all devices are implanted according to the device specific 
Instruction for Use (IFU) and/or Operating Room (OR) manuals and the site or physician’s standard of care.  
 Patient data will be collected from the baseline/pre- operative visit, the procedure, and 
follow up evaluations which will occur according to each physician’s standard of care, up to [ADDRESS_278056] -operatively. A 1=year follow up evaluation will be required, and a 2-
year follow -up evaluation will be strongly encouraged. Follow -up evaluations may occur 
during visits with the physician  and/or by [CONTACT_230861].   
 Each physician will determine if the device implantation procedure was successful based on his/her standard of care. Any reported intra- operative complications will be 
collected in the registry database. Success will be measured post -operatively by 
[CONTACT_230862].  
 The PROPPER Registry is designed to obtain post market safety and effectiveness information as well as to serve as an active surveillance system for collecting device 
related events or complications and malfunctions  in patients implanted with BSC penile 
prostheses  and reporting product complaints to BSC. This will provide a robust 
database of clinical information from which a number of analyses can be performed.  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 16 of 55 5 PATIENT ELIGIBILITY  
The PROPPER Registry is expected to enroll approximately 500 to 1500 patients at up 
to 16 sites throughout the US and Canada. Enrollment is expected to be over a one to two year period with up to five year patient follow -up. 
5.1 INCLUSION CRITERIA 
Men diagnosed with erectile dysfunction (ED) for whom a BSC penile prosthesis is 
recommended by [CONTACT_230863].  Potentially eligible men should also meet the following inclusion criteria for study enrollment:  
• Willing and able to provide written informed consent prior to enrollment (if applicable)  
• Willing to be seen or contact[CONTACT_230864] [ADDRESS_278057] data records are entered into the database. A unique patient 
identifier will be assigned to each patient at enrollment (upon signing an ICF or database entry). The PROPPER Registry is expected to enroll approximately 500 to 1500 patients at up to 16 sites throughout the US and Canada. Enrollment is expected to be over a one to two year period with up to five year patient fol low-up.
  A total of more 
than 500 patients are anticipated to be implanted and entered into the registry database per year of enrollment. Based on historical estimates and assuming 10 to 15 participating physician s, the following number of each BSC penile prosthesis type will 
be implanted each year of enrollment : 500 AMS 700
® Inflatable Penile Prostheses, 15 
AMS Ambicor® Penile Prostheses, and 20Spectra™ Concealable Penile Prostheses .  
 
7 DATA COLLECTION  
Data will be collected via internet -based electronic data capture (EDC) with paper based 
questionnaires for collection of patient -reported outcomes (PRO) data. The PRO data 
will be entered into the registry database by [CONTACT_099] , physician staff  or BSC staff. 
The EDC module will be developed and maintained  by [CONTACT_71640]. 
 
Physicians are not required to complete all data fields in the database. Each will be asked to enter the required data at baseline/procedure and one- year follow -up for each 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278058] of care for treatment of ED.  
 This is an observational collection of prospective patient data, with the following data 
required for each enrolled physician  and patient:  
• basic practice information for each physician  
• baseline/pre- operative patient information:  age, race/ethnicity, primary etiology 
of ED, relevant concomitant medical conditions and concom itant medications that 
might impact ED  
• implantation surgery data:  date of procedure, surgical approach, implant model 
type, drain, dressing, concurrent procedures, significant corporal fibrosis or 
scarring noted, curvature correction procedure(s) (e.g., for Peyronie’s disease) , 
and patient status post -op  
• 1- year post -operative follow -up (at a minimum):  each patient is asked [ADDRESS_278059] any potential device 
related complications and their outcomes, patient  satisfaction with implanted 
device(s) and use of device.  
 
Refer to Table [ADDRESS_278060] -
implantation patient satisfaction with the device and use of the device:  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 18 of 55 • How satisfied are you with the device(s) ? (5-point scale)  
1 – Very Dissatisfied  
2 – Dissatisfied  
3 – Neither  Satisfied  nor Dissatisfied  
4 – Satisfied   
5 – Very Satisfied  
• Are you using the device?  (Y/N) 
o (If yes )  How often are you using the device? (less than once per month, 
or more than once per month)   
o How many times per month?  
o If no, why aren’t you using the device? (Loss of partner, partner 
disinterest, device problem, device dissatisfaction, health decline, other, other device use reason)  
o If yes, and not using the device as often as desired, or if dissatisfied with the device, indicate why (Loss of partner, partner disinterest, device problem, device dissatisfaction, health decline, other, other device use reason)  
 
7.2 DEPRESSION HISTORY QUESTIONS  
The following patient questions used to assess depression will be optional at baseline 
and at each annual follow -up. 
• Have you had any office visits in past year for treatment of depression? (Y/N)  
o If Yes: App roximately how many visits ? 
o If Yes: Are you taking any medication for treatment of depression?  
 If Yes:  How many months have you taken the medication?  
 7.3 PATIENT QUESTIONNAIRES  
Patient questionnaires to measure effectiveness will be optional at baseline and  at all 
follow -ups. The following validated, patient -reported outcome questionnaires are 
strongly  recommended  for all patients at baseline and follow -up: 
• IIEF-5/SHIM erectile function questionnaire  
• EHS erection hardness questionnaire  
• SF-12 health- related  quality of life (HRQOL) questionnaire  
 
The following validated, patient -reported outcome questionnaires are recommended for 
all patients with post -prostatectomy ED or incontinence:  
• AUA-SI/IPSS urinary symptom questionnaire s  
• UCLA -PCl urinary, sexual and bowel function and bother questionnaire 
 The questions for each individual questionnaire are provided in the Appendix.  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 19 of 55 7.3.1  International Index of Erectile Function-5 / Sexual Health Inventory for 
Men (IIEF-5/SHIM)  
The IIEF -5 (also known as the SHIM ) is a validated, self -report questionnaire with a 25-
point maximum score, summed from responses  to four questions derived from the 
erectile function domain (items 2, 4, 5, and 15) and one question from the intercourse 
satisfaction domain (item 7) of the broader validated 15- item IIEF questionnaire used to 
assess sexual function in multiple domains.  Severity of ED is categorized based on the 
following IIEF -5 domain scores established and validated in previous studies:  
Severe—5 to 7 Moderate—8 to 11  
Mild-Moderate—12 t o16  
Mild—17 to 21  
No ED—22 to 25  
 
7.3.2  EHS Erection Hardness Questionnaire 
Patient s will be asked to respond to the Erection Hardness Score (EHS) questionnaire 
once per year or at each follow -up visit  to assess erection hardness based on their most 
recent sexual encounter(s).  The EHS has a range of responses from 0 to 4 with higher 
scores corresponding to a more firm or rigid erection. 
 
7.3.3  SF-12 Health -related Quality of Life (HRQOL) Questionnaire 
The SF -12v.2 Health Survey is a generic measure and does not target a specific age or 
disease group. It is a shorter version of the SF -36V2 Health Survey that uses 12 
questions to measure function health and well -being from the patient’s point of view.  
The SF -12 quantifies HRQOL into two composite scores, the Physical C omponent 
Summary (PCS) and Mental Component Summary (MCS) scales.   This survey  also 
quantifies HRQOL into the same eight multi -item subscale domains used in the SF -36 
with one or two questions in each domain:  physical functioning, emotional well -being, 
general health, pain, energy, social functioning, and role limitations (problems with work 
or other daily activities ) as a result of  physical or emotional health.  Each individual 
domain and the component summary scores (PCS and MCS) are calculated and converted to a standardized 0- 100 scale, with higher scores indicating better HRQOL.  
 
 
7.3.4  American Urological Association – Symptom Index (AUA-SI)  
THE AUA- SI (comprised of 7 of the 8 questions of the International Prostate Symptom 
Score, or IPSS) is used to quantify urinary irritative/obstructive symptom frequency and severity and is scored on a scale of 0– 35 based on the summary of the values for each 
item, with higher scores corresponding to worse outcomes.  Classification of urinary 
irritative/obstructive symptoms based on these scores are as follows:  
Mild – 0 to 7  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 20 of 55 Moderate – 8 to 19  
Severe – 20 to 35  
 
7.3.5  UCLA-Prostate Cancer Index (UCLA-PCI) Questionnaire 
The UCLA -PCI assesses disease -specific, organ targeted health related quality of life 
(HRQOL) in six scales or  domains that are of special concern to men treated for 
prostate cancer. Each  UCLA PCI domain is scored on a scale of 0– [ADDRESS_278061] of potential adverse device effects and surgery or device related complications that may occur during or after  the implantation of the BSC devices 
can be found in the device specific IFU and/or OR and Patient Manuals.   
 As per the OR Manual for the penile prosthesis, after penile prosthesis implantation, the Principal Physician  is responsible for checking with the patient for any signs of 
complications, and for reporting device complications in compliance with local regulations (e.g. IRB/EC, country) for a market -released device.  The physician should 
continue to have contact [CONTACT_230865] (e.g., cylinders losing rigidity), and to check for signs of complications such as infection or erosion.  Patients should be instructed to discuss any changes noticed in the function of their prosthesis or problems that may develop after implantation surgery with their physician.   
       
7.4.1  CLINICAL STUDY EVENTS  
 
Clinical study events to be collected for assessment of safety include complications 
(adverse device effects/events), device malfunctions, and revision procedures related to the device or implantation procedure.  At follow -up, including the required 1- year post -
operative visit  or telephone call , the following standardized, non- validated question will 
be used to determine whether any complications with the device have occurred: 
•  Have you had any surgery on your penis  or problems with the device since your 
penile prosthesis  was implanted? (Y/N)   
  A clinical study event data form will be provided to record any events that occur during or after surgical implantation of a BSC penile prosthesis device.  Any reported intra-
operative or post-operative device or surgery related complications should be recorded 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 21 of 55 at the time of procedure and any follow -up visits (for BSC products only). The 
informa tion recorded will include the following:  
• Complication  
• Treatment  
• Location of treatment  
• Resolution (Resolved or Continuing)  
 
BSC personnel will follow up with the physician to obtain additional available details, if 
needed, related to any reported complication that results in a serious adverse device effect , or device deficiency that could have led to a serious adverse device effect, or is 
severe and may pose unreasonable risk, or potential for death, or serious injury to the patient.   
 
7.4.[ADDRESS_278062] complaint associated with a BSC device being reported directly to BSC Consumer 
Affairs and any appropriate regulatory authority without any additional action required by [CONTACT_099] .  If a reportable event is identified, BSC Consumer Affairs will seek to 
obtain as much of the following information as possible: name [CONTACT_122730], lot series number (if known), source of data/ physician, event description, event start date, date of 
BSC notification, medical action taken, patient outcome (if known), investigation results, 
corrective action taken (if any), and regulatory reports (if any).  These additional details 
for any device complaint will not  be recorded in the Registry study database.   
 The Principal Physician  will be responsible for reporting events to the IRB/EC based on 
local requirements.  The Principal Physician  will also be responsible for reporting any 
device complications that occur after the time of study exit and all updates to device 
complications that are unresolved at the time of study exit using the usual process applicable to market -released devices.   
 
7.4.3  SAFETY REPORTING  
Definitions and Classification  
Adverse event definitions are provided in Table 2. Administrative edits were made to combine 
definitions from ISO [ZIP_CODE] and MEDDEV 2.7/3 (2015).      
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 22 of 55 Table 2: Safety Definitions  
Term  Definition  
Adverse Event (AE)  
 
Ref: ISO [ZIP_CODE] -2011  
 
Ref: MEDDEV 2.7/3 (2015)  
 
 Any untoward m edical occurrence, unintended disease or 
injury, or any untoward clinical signs (including an abnormal laboratory finding) in subjects, users or other persons, 
whether or not related to the investigational medical device.  
Serious Adverse Device 
Effect (S ADE)  
 Ref: ISO [ZIP_CODE] -2011  
 
Ref: MEDDEV 2.7/3 (2015)  Adverse event that:  
a.            Led to death,  
b.            Led to serious deterioration in the health of the subject, that either resulted in as defined by [CONTACT_5640]:  
1. a life -threatening illness or injury, or  
2. a permanent impairment of a body structure or a body 
function, or  
3. in-patient or prolonged hospi[INVESTIGATOR_059], or  
4. medical or surgical intervention to prevent life- threatening 
illness or injury or permanent impairment to a body structure 
or a body function,  
c.            Led to fetal distress, distress death or a congenital 
abnormality or birth defect.  
 
NOTE: Planned hospi[INVESTIGATOR_272] a pre- existing condition, 
or a procedure required by [CONTACT_230866], 
without serious deterioration in health, is not considered a 
serious adverse event.  
Unanticipated Adverse 
Device Effect (UADE)  
 
Ref: [ADDRESS_278063], problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that 
relates to the rights, safety, or welfare of subjects.   
Unanticipated Serious 
Adverse Device Effect ([LOCATION_003]DE)  
 
Ref: ISO [ZIP_CODE] -2011  
 
Ref: MEDDEV 2.7/3 (2015)  
 Serious adverse device effect which by [CONTACT_5942], 
incidence, severity, or outcome has not been identified in the current version of the risk analysis report.  
  
NOTE 1 : Anticipated serious adverse device effect (ASADE) 
is an effect which by [CONTACT_5942], incidence, severity or outcome has been identified in the risk analysis report.  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 23 of 55 Table 2: Safety Definitions  
Term  Definition  
 
Device Deficiency  
 
Ref: ISO [ZIP_CODE] -2011  
 
Ref: MEDDEV 2.7/3 
(2015)  An inadequacy of an investigational medical device related 
to its identity, quality, durability, reliability, safety or 
performance. This may include malfunctions, use error, or inadequacy in the information supplied by [CONTACT_3455].  
 
   Relationship to Study Device(s)  
The investigator must assess the relationship of the AE to the study device as related or unrelated. See criteria in Table 3:  
 
Table 3: Criteria for Assessing Relationship of Study Device to Adverse Event  
Classification  Description  
Unrelated  • The adverse event is determined to be due to a concurrent 
illness or effect of another device/drug and is not related to 
the investigational product.  
Related  • The adverse event is determined to be potentially related to 
the investigational product, and an alternative etiology is equally or less likely compared to the potential relationship to investigational product, or  
• There is a strong relationship to investigational product, or 
recurs on re- challenge, and another etiology is unlikely, or  
• There is no other reasonable medical explanation for the 
event.  
 
Relationship to Study Procedure 
The investigator must assess the relationship of the AE to the study procedure as unrelated, 
possibly related, or probably related. See criteria in Table 4:  
 
Table 4: Criteria for Assessing Relationship to Study Procedure  
Classification  Description  
Unrelated  • No evidence that the timing of the adverse event has a 
relationship to the procedure performed.  
Related  • The adverse event has a timely relationship to procedure 
performed.   
However, a potential alternative etiology may be responsible for the 
adverse  event.  
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278064] ICAL METHODS AND DATA ANALYSIS  
Analyses of multi -center data for initial publication(s) may be performed after 
approximately 500 patients complete 1 year follow -up.  Additional individual and multi -
center data analyses may be performed as warranted throughout the study for 
publication(s). Analysis for study publications is planned after the study enrollment is complete and all the enrolled patients have completed their 1-year and 5-year follow -up 
evaluations.  
 
8.1 
 SAMPLE SIZE   
Up to 1500 patients with erectile dysfunction (ED) electing to receive a BSC penile 
prosthesis implant will be included in this registry over a 1- to 2-year enrollment period.  
A total of more than 500 patients are anticipated to be implanted and entered into the 
registry database per y ear of enrollment, based on the following BSC historical 
estimates of the number of each BSC penile prosthesis type implanted, and assuming 
10 to 15 participating physician s: 
• 500 AMS 700 ®  
• 15 AMS Ambicor ® 
• 20 Spectra™  
 
The minimum sample size for multi -center data analysis will depend on the total number 
of patients, or the number of patients with each type of penile prosthesis implanted for whom sufficient follow -up data on multiple endpoints of interest are available.  
Generally, a minimum follow -up of at  least one year after implantation is desired for 
analysis of data for the device subsets with previous clinical outcomes reported in the literature (e.g., AMS 700
®, AMS Ambicor ®).  Because clinical data has been published 
from multiple studies including more than 100 patients implanted with AMS 700 ® 
devices in the past decade (since the introduction of the InhibiZone antibiotic -
impregnated devices and the current MS Pump), analysis of less than [ADDRESS_278065] one1 year of follow -up is not planned.  
However, an analysis sample size as small as 10 to 25 patients implanted with the newer Spectra™ or AMS 700
® Series devices with the Conceal Low Profile reservoir, 
with [ADDRESS_278066] -
operative device or surgery related clinical study events recorded during the 
implantation or any follow -up visits (for BSC products only).   
 
Endpoint:  
• Complications (adverse device effects/events)  
o Intra-operative device or surgery related complications - reported during 
Implantation visit (e.g., cylinder crossover)  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278067]- operative device or surgery related complications - reported during 
follow -up (e.g., mechanical malfunction, infection)  
o Unanticipated and serious adverse device effects (per ISO [ZIP_CODE]:2011)  
o Deaths (related to the device or implantation procedure)  
 
• Device Malfunctions  
o Device deficiencies or malfunctions (per ISO [ZIP_CODE]:2011)   
 
• Revision procedures related to the device or implantation procedure  
 
Statistical Analysis:  
Descriptive statistics (numbe r of events, number and proportion of patient s) will be 
summarized by [CONTACT_230867].  Kaplan-
Meier method will be used to estimate the major complication event rate at [ADDRESS_278068] -
operative follow up by [CONTACT_230868][INVESTIGATOR_840] . 
 
Descriptions will also be prepared of the following details associated with device related complications in each category, and will include the following as available for each:  
• Treatment for compl ication  
• Location of treatment  
• Resolution (resolved or continuing)  
 Additional analyses may be prepared for other follow -up time such as 6 month, 2, 3, 4, 
and 5 years.  
      
Determination of Patients  for Analysis:  
All enrolled patients  that received a BSC penile prosthesis with data available will be 
included.  
8.3  EFFECTIVENESS OBJECTIVES  
Effectiveness of the BSC penile prostheses will be assessed in all patients with data 
available at the required 1- year (± 4 months) post -operative follow -up, and any of the 
following additional follow -up time points with data available:  
• 3 months (± 1 month)  
• 6 months (± 1 month)  
• 18 months (± 1 month)  
• 2 years (± 4 months)  
• 3 years (± 6 months)  
• 4 years (± 6 months)  
• 5 years(± 6 months)  
 
8.3.1  EFFECTIVENESS OBJECTIVE 1 – DEVICE USE AND SA TISFACTION  
To assess post -implantation patient satisfaction with the device and use of the device.  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 26 of 55  
Endpoint:  
• How satisfied are you with the device(s)? (5- point scale)  
1 – Very Dissatisfied  
2 – Dissatisfied  
3 – Equally Satisfied and Dissatisfied  
4 – Satis fied   
5 – Very Satisfied  
• Are you using the device?  (Y/N)  
o (If yes)  How often are you using the device? (less than once per month, 
or more than once per month)  
o How many times per month?  
o If no, why aren’t you using the device? (Loss of partner, partner 
disinterest, device problem, device dissatisfaction, health decline, other, 
other device use reason)  
o If yes, and not using the device as often as desired, or if dissatisfied with the device, indicate why (Loss of partner, partner disinterest, device problem , device dissatisfaction, health decline, other, other device use 
reason)  
 
Statistical Analysis:  
The number and percentage of patient s with responses in each category for the 
satisfaction and the device use questions at 1 -year visit and any of the additional follow -
up time points with data available will be summarized for each device type and overall for all BSC penile prostheses recipi[INVESTIGATOR_840].  
 
Determination of Patient s for Analysis:  
All enrolled patient s that received a BSC penile prosthesis with data available will be 
included.  
8.3.2  EFFECTIVENESS OBJECTIVE 2 – IIEF-5/SHIM QUESTIONNAIRES  
To assess sexual function in IIEF -5 scores.  
 
Endpoint:  
The endpoint is the change in IIEF -[ADDRESS_278069] -operative 
follow -up.  
 
Statistical Analysis : 
The IIEF -[ADDRESS_278070] deviation ( SD), and range wi ll be 
generated by [CONTACT_230869][INVESTIGATOR_840]. For 
within patient  change at [ADDRESS_278071] may be used when applicable.   
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278072] -treatment time point for 
each device type and overall : 
o ≤ 7 points (severe ED)  
o 8 to 11 points (moderate ED)  
o 12 to16 points (mild- moderate ED)  
o 17 to 21 points (mild ED)  
o ≥ 22 points (no ED)  
 
Determination of Patient s for Analysis:  
All enrolled patient s that received a BSC penile prosthesis with data available wi ll be 
included.  
 
8.3.3  EFFECTIVENESS OBJECTIVE 3 – EHS QUESTIONNAIRES   
To assess erection hardness based on patients’ most recent sexual encounters.  
 
Endpoint:  
The endpoint is the change in the single- item EHS scores from baseline to 1- year 
 post-operative fol low-up.  
 
Statistical Analysis:  
The EHS scores will be computed for each patient  at baseline and 1- year follow up, and 
the change from baseline to 1- year follow up will be calculated.  Descriptive summary 
statistics including mean, median, SD, and range will be generated by [CONTACT_230870][INVESTIGATOR_840]. For within patient  change at [ADDRESS_278073] may be used when 
applicable.   
 Additional analyses may also be used to summarize the values at the other follow -up 
time points with data available along with changes from baseline for each device type 
and overall for all BSC penile prostheses recipi[INVESTIGATOR_840]. Mixed effects model may be used 
to estimate the change from baseline across follow up visits when appropriate.  
 In addition, the number and percentage of patients who meet the following criteria will be calculated at baseline and each follow  up visit for each device type and overall : 
• Patients with an EHS score ≥ 3  (penis hard enough for penetration but not 
completely hard)  
• Patients with an EHS score =  4 (penis completely hard and fully rigid)  
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 28 of 55 Determination of Patient s for Analysis:  
All enrolled patient s that received a BSC penile prosthesis with data available wi ll be 
included.  
 
8.3.4  EFFECTIVENESS OBJECTIVE 4 – SF-12 HRQOL QUESTIONNAIRES  
To measure function health and well -being from the patient’s point of view.  
 
Endpoint:  
The endpoint is the change in each of the following SF -[ADDRESS_278074]-operative follow -up.  
 
Two component summary scales:  
• PCS (physical component summary)  
• MCS (mental component summary)  
Eight individual domain scales:  
• Physical functioning  
• Role physical  
• Emotional well- being 
• Role emotional  
• Social functioning  
• Energy  
• Pain 
• General health  
 
Statistical Analysis:  
The PCS, MCS and individual domain scores will be computed for each patient  at 
baseline and 1- year follow up, and the change from baseline to 1- year follow up will be 
calculated. Descriptive summary statistics including mean, median, SD, and range will be generated for each device type and overall for all BSC penile prostheses recipi[INVESTIGATOR_840]. 
For within patient  change at [ADDRESS_278075] may be used when applicable.   
 Additional analyses may also be used to summarize the values at the other follow -up 
time points with data available along with changes from baseline for each device type 
and overall for all BSC penile prostheses recipi[INVESTIGATOR_840]. Mixed effects model may be used 
to estimate the change from baseline across follow up visits when appropriate.  
 
Determination of Patient s for Analysis:  
All enrolled patient s that received a BSC penile prosthesis with data available will be 
included.  
 
8.3.5  EFFECTIVENESS OBJECTIVE 5 – AUA- SI/IP SS QUESTIONNAIRES   
To quantify urinary irritative/obstructive symptom frequency and severity.  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 29 of 55  
Endpoint:  
The endpoint is the change in the AUA -SI total scores from baseline to 1- year 
 post-operative follow -up.  
 
Statistical Analysis:  
The AUA -SI total scores will be computed for each patient  at baseline and 1- year follow 
up, and the change from baseline to 1- year follow up will be calculated. Descriptive 
summary statistics including mean, median, SD, and range will be generated for each 
device type and over all for all BSC penile prostheses recipi[INVESTIGATOR_840]. For within patient  
change at 1- year follow up compared to baseline, signed rank sum test or paired t -test 
may be used when applicable.   
 
Additional analyses may also be used to summarize the values at the other follow  up 
time points with data available along with changes from baseline for each device type 
and overall for all BSC penile prostheses recipi[INVESTIGATOR_840]. Mixed effects model may be used 
to estimate the change from baseline across follow up visits when appropriate.  
 In addition, the number and percentage of patients who meet the following criteria will be calculated at baseline and each follow  up visit:  
• Mild (0 to 7)  
• Moderate (8 to 19)  
• Severe ( 20 to 35)  
 
Determination of Patient s for Analysis:  
All enrolled patient s that received a BSC penile prosthesis with data available will be 
included.  
 
8.3.6  EFFECTIVENSS OBJECTIVE 6 – UCLA -PCI QUESTIONNAIRES   
To assess disease -specific, organ targeted health related quality of life in six scales or 
domains that are of special  concern to men treated for prostate cancer.  
 
Endpoint:  
The endpoint is the change in each of the following UCLA -PCI domains from baseline to 
1-year post-operative follow  up.  
 
• Sexual Function  
• Sexual Bother  
• Urinary Function 
• Urinary Bother  
• Bowel Function  
• B owel Bother  
 
Statistical Analysis:  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278076] may be used when applicable.   
 
Additional  analyses may also be used to summarize the values at the other follow -up 
time points with data available along with changes from baseline for each device type 
and overall for all BSC penile prostheses recipi[INVESTIGATOR_840]. Mixed effects model may be used 
to estimate the change from baseline across follow up visits when appropriate.  
 
Determination of Patient s for Analysis:  
All enrolled patient s that received a BSC penile prosthesis with data available will be 
included.  
 
8.3.7  ADDITIONAL EFFECTIVNESS OBJECTIVES   
To assess the penile length and girth, number of pads used daily and pad weight (24-
hour test).  
 
Endpoint:  
The endpoint is the change in each of the following measurements from baseline to [ADDRESS_278077]-operative follow -up.  
 
• Inflated penile length measurement (measured from suprapubic fat pad to tip)  
• Inflated penile girth measurement  (circumference measured 1cm proximal to the 
proximal end of the corona)  
• Number of pads used daily (if incontinence indicated pre- operatively)  
• Pad weight (24- hour test) (if incontinence indicated pre- operatively)  
 
Statistical Analysis:  
Descriptive summary statistics for penile length and girth, number of pads used daily and pad weight at baseline and 1- year follow up, and the change from baseline and 1-
year follow up will be calculated and summarized for each device type and overall for all 
BSC penile prostheses recipi[INVESTIGATOR_840]. For within patient  change at [ADDRESS_278078] may be used when 
applicable.   
 Additional analyses may also be used to summarize the values at the other follow  up 
time points with data available along with changes from baseline for each device type 
and overall for all BSC penile prostheses recipi[INVESTIGATOR_840].  
 
Determination of Patient s for Analysis:  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 31 of 55 All enrolled patient s that received a BSC penile prosthesis with data available will be 
included.  
8.4  ADDITIONAL DATA ANALYSIS  
8.4.1  SUBGROUP ANALYSIS  
Subgroups of patients for which analyses of safety and effectiveness outcomes may be 
performed based on relevant available data include, but are not limited to, the following:  
 
• Implant type and model (AMS 700 ®, Ambicor ®, Spectra ™) 
o AMS 700 ® LGX  
o AMS 700 ® Series with Conceal  
o AMS 700 ® MS Pump  
o AMS 700 ® with InhibiZone  
• Original (virgin) and revision implants (if revision – with or without w ashout)  
• Primary etiology of ED (e.g., Diabetes, Cardiovascular disease, Radical 
prostatectomy, Peyronie’s disease)  
 
8.4.2  PHYSICIAN DATA   
Recorded data from each practice will be summarized in the following categories :  
• Practice type (private or academic)  
• Main  setting for procedures (Hospi[INVESTIGATOR_230839])  
• Standard device cycling instructions to patients receiving IPPs (number and 
percentage) – a description of each physician’s recorded device cycling 
protocol will also be prepared.  
8.4.3  BASELINE/ PRE- OPERATIVE DATA  
The following demographic and patient characteristics will be summarized (including 
mean, median, and standard deviations) for patient groups based on the type of BSC 
device implanted and overall for all BSC penile prostheses recipi[INVESTIGATOR_840]:  
• Age 
• Duration of ED (y ears or months)  
• Pre-op flaccid penile length (measured from suprapubic fat pad to tip)  
• Pre-op stretched penile length (measure from suprapubic fat pad to tip)  
• Pre-op flaccid girth (circumference measured 1cm proximal to the proximal 
end of the corona)  
• Numb er of office visits in past year for treatment of depression  
• Duration (weeks) and Frequency (times/day) of VED use prescribed pre-operatively   
• Number of pads used daily (for SUI)  
• Pad weight (24- hour test) (for SUI) 
• Urodynamics (for SUI):  Post -void residu al (PVR) volume (ml), maximum flow 
rate (ml/sec)  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 32 of 55  
The number and percentage of patients with recorded baseline data will also be summarized within each device type and the full patient group in the following categories:  
• Race/Ethnicity  
• Primary etiology of E D 
o  Organic  
 Diabetes  
 Cardiovascular disease 
 Neurologic disorder  
 Peyronie’s disease  
 Other organic (specify)  
o Acute 
 Radical prostatectomy (RP) (robotic, open or laparoscopic)  
 Radical pelvic surgery (other than RP)  
 Pelvic radiation therapy  
 Pelvic trauma or inj ury 
 Spi[INVESTIGATOR_1828]  
 Venous Leak  
 Priapi[INVESTIGATOR_8801]  
 Other acute (specify)  
 
• Concomitant medical conditions and concomitant medications:   
o premature or rapid ejaculation/PE  
o climacturia  
o cardiovascular disease  
o diabetes  
o Peyronie’s disease  
o steroid use  
o anticoagulant  use  
o anti-depressant use  
o Venous Leak  
o stress urinary incontinence/SUI  
 Etiology of incontinence (radical prostatectomy, pelvic irradiation, and other)  
 Previous treatment(s) for incontinence (behavior modification, pelvic floor muscle training, transobturat or male sling, artificial 
urinary sphincter/AUS, and other)  
 Cystoscopy findings (bladder neck contracture, other) (for SUI)  
 Any detrusor overactivity (DO) or detruser sphincter dyssynergia (DSD) (for SUI)  
o any others recorded  
• Previous treatments used for ED (PDE-5 inhibitor, VED, ICI, combination 
therapi[INVESTIGATOR_014], previous/failed penile implants ) 
• Patients with any office visits in past year for treatment of depression  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 33 of 55 • Patients taking any depression medication in past year  
• Patients with VED and/or penile traction therapy  prescribed pre- operatively  
8.5 IMPLANTATION DATA  
Descriptive summaries of all available implantation data collected in the registry 
database will be prepared, to include the number of patients (and percentage or range of values, as applicable) with recorded data within each device type and the full patient group in the following categories:  
 
• Date of procedure (range)  
• Original (virgin) , revision , salvage, or replacement  implant (if revision  or salvage, 
with or without washout)  
• Surgical approach (percentage of patients by [CONTACT_17203]:  Penoscrotal (PS), Infrapubic (IP), Subcoronal (SC) and Other)  
• Implant model type  
o Spectra™ Concealable Penile Prosthesis  
 Cylinder diameter (9.5, 12, 14 mm)  
 Cylinder length (12, 16, 20 cm)  
 Total number of RTEs per cylinder (0, 1, 2)  
 Total length of RTEs per cylinder (specify: 0.5 to 7.5 cm)  
o AMS Ambicor
® Penile Prosthesis (2- pi[INVESTIGATOR_230841])  
 Cylinder diameter (12.5, 14, 15.5 mm)  
 Cylinder length (14, 16, 18, 20, 22 cm)  
 Total number of RTEs per cylinder (0, 1, 2, 3, 4)  
 Total length of RTEs per cylinder (specify: 0.5 to 6.5 cm)  
o AMS 700 ® Penile Prosthesis (3– pi[INVESTIGATOR_230841])  
 InhibiZone- impregnated  
 Cylinder type (CX, LGX, CXR, Ultrex, CXM)  
 Cylinder length (10, 12, 14, 15, 16, 18, 21, 24  cm) 
 Total number of RTEs per cylinder (0, 1, 2, 3, 4)  
 Total length of RTEs per cylinder (specify: 0.5 to 7.5 cm)  
 Pump type (MS Pump, Tactile pump, Inflate/Deflate)  
 Preconnect  
 Reservoir (Spherical 65 ml, Spherical 100 ml, Conceal 100 ml)  
 Reservoir placement (space of Retzius , Sub -muscular , Sub 
Scarpas’s fascia,  other)  
 Reservoir separate incision  
• Drain (None or Type)  
• Dressing (None, compression/mummy wrap, non- compressive dressing)  
• Concurrent procedures (ventral phalloplasty, ligament release, circumcision, 
suprapubic fat pad reduction, spermat ic cord/testicular procedure, AUS (including 
single or multiple incision), sling – (including sling type and single or multiple 
incision)  
• Significant corporal fibrosis or scarring noted  
• Peyronie’s Disease  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 34 of 55 o Initial intraoperative curvature measurement (angle of curvature with 
inflated device using a goniometer or protractor)  
o Any curvature correction procedure(s) performed (including correction technique (Wilson/Delk remodeling, tunical incision, incision and grafting, or plication)  
 Curvature measurement after correction  
 Second correction procedure(s) (including summary details as above)  
• Patient status post -op (Admitted/inpatient/≥24 hours, same day 
discharge/outpatient/<24 hours)  
o Number of days in the hospi[INVESTIGATOR_230842] (mean, median, standard d eviation)  
• Length of procedure (mean, median, standard deviation)  
• Intra-operative penile length measurement with device fully inflated (mean, 
median, standard deviation)  
• Intra-op penile girth measurement with device fully inflated (mean, median, 
standard deviation)  
• Intra-op stretched penile length with device deflated (mean, median, standard 
deviation)  
• Foley in place at discharge 
 
9 PROTOCOL DEVIATIONS  
All attempts should be made not to deviate from the clinical protocol. If , however, a 
Protocol Deviation  occu rs a Protocol Deviation data form  should be recorded  for each 
study protocol deviation (e.g., failure to obtain  written  informed consent  if required , 
enrolling a patient  who does not meet inclusion criteria, not obtaining minimum  required 
follow -up data).  This form will include a description of the deviation, reason for 
deviation, and corrective and/or preventative action, if necessary. The Principal 
Physician  is responsible for reporting protocol deviations in compliance with their 
IRB/EC regulations. BSC will determine and document whether the data obtained from 
patient(s) with one or more protocol deviations are sufficient to be included in the study 
outcomes analyses prior to locking the data for the analyses.  
 
[ADDRESS_278079] some summary data.  Aggregate data from more 
than one site will be made available to Principal Physician (s) only upon approval of a 
request by [CONTACT_230871] . To preserve anonymity, 
aggregate data may not be made available until a minimum of [ADDRESS_278080] been 
enrolled into the Registry .   
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278081] access only to data from their own sites; they 
will not have access to data from other sites.  
12 DATA QUALITY ASSURANCE  
The EDC system will include edit checks that will inform physician s as soon as they 
enter inappropriate data. There are 2 levels of edit checks: soft and hard. ‘Soft’ errors result in a pop- up message that notes the nature of the error and a confirmation request 
of the value in question. ‘Hard’ errors generate similar error messages, but also prevent 
the form from further data entry until the error is corrected. An example of a soft error generation is entering an out of range value, for example a dry pad weight value of 20g and a pad weight after test value of 10g, would be outside the expected value of pad weight difference. An example of a hard error is failing to respond ‘yes’ to the question: ‘Was Informed Consent/HIPAA waiver obtained (per your IRB/EC requirements)?’. Validation tests of this edit check system have been performed by [CONTACT_230872].  
 
[ADDRESS_278082] (IRB)/ ETHICS COMMITTEE  (EC) R EVIEW  
This registry  will be performed in accordance with all applicable requirements set forth 
in the ICH Good Clinical Practices (GCPs), the World Medical Association Declaration 
of Helsinki, ISO [ADDRESS_278083] all been cleared for marketing by [CONTACT_230873]. Physicians are 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278084] to an IRB/EC for review and approval if required prior to patient enrollment at each site. All physicians must comply 
with the requirements of their IRB/EC.  
15 INFORMED CONSENT AND PATIENT PRIVACY  
BSC will provide a template Informed Consent Form describing this study for physicians 
at each participating site to submit to their IRB/ECs.  All physician s must comply with 
the requirements of their IRB/EC. If an IRB/EC requires patients to provide informed consent to participate in this study, a site- specific Informed Consent Form will be 
submitted for IRB/E C review and approval prior to patient enrollment at the site.   
Because this registry study is non- interventional and physician s are using standard- of-
care treatment and assessments in this study, the IRB/EC at some sites may not require written informed consent from patients prior to their participation in this study.  If 
study -specific informed consent is not required at a site, a waiver from informed consent 
must be documented from the site’s IRB/EC prior to study patient enrollment.   A site’s 
IRB/EC may  require that an approved HIPAA authorization be signed instead of, or in 
addition to, informed consent prior to enrollment of study patients.  
 16 STUDY RECORDS AND REPORTS  
Data from this study related to the safety or performance of the BSC penile prostheses  
may be submitted to regulatory authorities.  Study records will be maintained by [CONTACT_230874]/ ICH and ISO  ICH Good Clinical 
Practice (GCP) guidance and standards [FDA/ICH E6 Guidance, April 1996; ISO 
[ZIP_CODE]:2011(E) ].  The physician  is responsible for  maintaining  accurate, complete, and 
current records and documents relating to the conduct of this study  as outlined in the 
GCP  standards, including the following:   
• Clinical investigational plan (CIP/protocol) and any a mendments  
• Signed Investigator agreement and clinical study reimbursement agreement  
• Physician  curriculum vitae (CV) (current by [CONTACT_49761] ) 
• Physician  medical license (current by [CONTACT_568])  
• Physician  financial disclosure information  
• Study personnel training records  (BSC to provide)  
• IRB/EC composition, approvals, renewals and correspondence  (as applicable)  
• Delegat ion of Authority Log (BSC to provide)  
• Study related correspondence with another physician , an IRB/EC, BSC , 
monitors, patients, or responsible regulatory authority, including required reports that relate to this study  
• Patient’s medical records  
• Signed study Informed Consent Form for each patient (ICF, if required)  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 37 of 55 • Patient questionnaires (if used)  
 
All records pertaining to this clinical study  will be maintained for at least [ADDRESS_278085] occur and be reported to BSC  not more than 30 days after the transfer occurs.  
 
16.1 PHYSICIAN R EPORTS  
 
Physician  is responsible for preparation and submission of the following reports as 
identified in Table 5 below.  
 
Table 5: Description and Submission Requirements of Physician Reports  
Report  Submit to  Description  
Clinical Study Events  Sponsor/IRB/EC  Unanticipated adverse device Effect (UAD E), 
and Serious Adverse Device Effect (SADE) 
need to be submitted to the Sponsor  and may 
need to be submitted to the IRB/EC  in 
accordance with the IRB/EC requirements at the 
study  site, as soon as possible but no later than 
10 working days  after the physician learns of the 
event  
Study Patient  Death  Sponsor/IRB/EC  Death must be reported to the sponsor and may 
need to be submitted to the IRB/EC in 
accordance with local requirements , no later 
than 10  working days  after the physician learns 
of the death 
Withdrawal of IRB/EC 
approval  Sponsor  The physician  must report a withdrawal of 
approval by [CONTACT_230875]/ IRB of the 
physician ’s part of the study , within 5 working 
days  of the phys ician learning of the withdrawal 
of approval  
Progress Report  Sponsor/IRB/EC  The physician  must submit this report to the 
sponsor and the IRB/EC at regular intervals in 
accordance with the IRB/ EC requirements at 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 38 of 55 the study  site 
Study Deviations  Sponsor/IR B/EC  Notice of deviations from the plan will be 
submitted to the sponsor and may need to be 
submitted to the IRB/EC in accordance with IRB/EC requirements  
Final Report  Sponsor/IRB/EC  Notification of clinical investigation close -out to 
the IRB/EC by [CONTACT_230876], where required.  
 
16.2 BSC REPORTS  
BSC is responsible for preparation and submission of the following reports as identified 
in Table 6 below.  
 
Table 6: Description and Submission Requirements of BSC Reports  
Report  Submit to  Description  
Unanticipated A dverse 
Device Effects  Physician s, 
FDA/CA, IRB /EC, 
(where required)  Notification within 10 working days after the 
Sponsor learns of the event  
Withdrawal of IRB/EC 
approval  Physician s, 
IRB/EC, (where 
required)  Notification within 5 working days  of the 
Sponsor learning of the withdrawal of approval  
Recall  Physician s, 
FDA/CA, IRB /EC 
(where required)  Notification within [ADDRESS_278086] that a 
physician  return, repair or otherwise dispose of 
any devices  
Final re port IRB/EC, 
Physician s (if 
required)  BSC will notify physician s and IRBs/ECs within 
[ADDRESS_278087] to withdraw from 
study participation at any time during the study.    
18 PUBLICATION PLAN  
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 39 of 55 Results of this study are intended to be submitted for publication in scientific journals 
and at scientific meetings.  Study data acquisition, analyses and interpretation of 
aggregate multi -center study data for all enrolled patients after completion of 1 -year 
follow -up and final study follow -up for publication will be overseen by [CONTACT_71640], in 
collaboration with actively participating physician(s) and study Publication Review 
Committee  members.  Additional statistical analysis or aggregate data publications 
describing study outcomes authored by [CONTACT_230877].   
 
The PROPPER Publication Review Committee will develop a charter describing its membership an d the details of the schedule and procedures for requesting data, 
analyses or other support related to publications for submission to scientific organizations.  This charter will be distributed to all participating physicians by [CONTACT_71640]. A 
BSC Clinical Project  Leader or designee will be the coordinat or for facilitating the 
submission of analysis or publication support requests by [CONTACT_230878].   
 Physician s will have access to the data from their own patients throughout the study 
and may perform independent analyses for publication(s). However, BSC requires that  
the author furnish a copy of any proposed publication to BSC for Publication Review 
Committee review prior to submission to the publisher.  
 Generally accepted criteria for publication authors hip will be considered appropriate for 
all study -related publications
72:   
 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data;  
2) drafting the manuscript or revising it critically for important intellectual content; and  
3) final approval of the version of the manuscript to be submitted for publication.  
 Each individual author should qualify for authorship, and all authors who qualify should be listed either as individual authors or as part of an authors’ group on study 
publications .  Each author should have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content.   Although BSC representatives 
may in some cases co- author publications, acquisition of data or general supervision of 
the study  alone does not qualify one for authorship.  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278088] 1999.  
 
2. Feldman HA, Goldstein I, Hatzichristou DG. Impotence and its medical and psychosocial correlates: results of the [LOCATION_005] Male Aging Study. J Urol. 1994;151(1):54– 61. 
 3. McKinlay JB, Digruttolo L, Glasser D. International differences in the epi[INVESTIGATOR_230843]. Int J Clin Pract Suppl. 1999;102:35.  
 4. Nelson CJ, Mulhall JP, Roth AJ. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. J Sex Med. 2011 Feb;8(2):560- 6. 
 5. Rosen R, Shabsigh R, Berber M, Assalian P, Menza M, Rodriguez -Vela L, Porto R, 
Bangerter K, Seger M, Montorsi F; Vardenafil Study Site Investigators. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression- related improvement with vardenafil for erectile response study. Am J 
Psychiatry. 2006 Jan;163(1):79- 87. PubMed PMID: 16390893.  
 6. Araujo AB, Travison TG, Ganz P, Chiu GR, Kupelian V, Rosen RC, Hall SA, McKinlay JB. Erectile dysfunction and mortality. J Sex Med. 2009 Sep;6(9):2445- 54. 
Epub 2009 Jun 15.  
 7. Schouten B, Bohnen AM, Thomas S. Erectile dysfunction and incidence of cardiovascular disease. JAMA. 2006 May 3;295(17):1999.  
 8. Schouten BW, Bohnen AM, Bosch JL, Bernsen RM, Deckers JW, Dohle GR, Thomas S. Erectile dysfunction pros pectively associated with cardiovascular disease in the 
Dutch general population: results from the Krimpen Study. Int J Impot Res. 2008 Jan-Feb;20(1):92- 9. Epub 2007 Aug 30.  
 9. McVary KT. Clinical practice. Erectile dysfunction. N Engl J Med. 2007 Dec 13;357(24):2472- 81. 
 10. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen 
PC, Harlan LC, Potosky AL: Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000, 283(3):354- 60. 
 11. Kundo SD, Roehl KA, Effener SE, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004; 172:2227- 2231  
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 41 of 55 12. Catalona, W. J., Carvalhal, G. F., Mager, D. E. a nd Smith, D. S.: Potency, 
continence and complication rates in 1,870 consecutive radical retropubic 
prostatectomies. J Urol, 162: 433, 1999.  
 13. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48- month quality -of-life outcomes after treatment for localized prostate 
cancer. J Natl Cancer Inst. 2009 Jun 16;101(12):888- 92. Epub 2009 Jun 9.  
 14. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic 
review: comparative effectiveness and harms of treatments  for clinically localized 
prostate cancer. Ann Intern Med. 2008 Mar 18;148(6):435- 48. Epub 2008 Feb 4. 
Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.  
 15. Bergman J, Gore JL, Penson DF, Kwan L, Litwin MS. Erectile aid use by [CONTACT_230879] l ocalized prostate cancer. J Urol. 2009 Aug;182(2):649- 54. Epub [ADDRESS_278089] 2002;94:430 –437. 
 17. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-
month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled t rial. JAMA. 
2004;292:821- 7. 
 18. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, et al. Canadian 
Uro-Oncology Group. Randomized comparative study of 3 versus 8 -month neoadjuvant 
hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001;166:500- 6; discussion 506- 7. 
 19. Padma -Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, 
Giuliano F, Brock G; Study Group. Randomized, double- blind, placebo- controlled study 
of postoperative nightly  sildenafil citrate for the prevention of erectile dysfunction after 
bilateral nerve- sparing radical prostatectomy. Int J Impot Res. [ADDRESS_278090];20(5):479-
86. Epub [ADDRESS_278091];54(4):924- 31. Epub 
2008 Jul 9.  
 21. Mulhall JP, Parker M, Waters BW, Flanigan R. The timing of  penile rehabilitation 
after bilateral nerve- sparing radical prostatectomy affects the recovery of erectile 
function. BJU Int. 2010 Jan 1;105(1):37- 41. Epub 2009 Jul 31.  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 42 of 55  
22. Ohebshalom M, Parker M, Guhring P, Mulhall JP. The efficacy of sildenafil citrate  
following radiation therapy for prostate cancer: temporal considerations. J Urol. 2005 Jul;174(1):258- 62; discussion 262.  
 23. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, 
Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Kl ein E, Kibel A, Pi[INVESTIGATOR_64982], Kuban 
D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate- cancer survivors. N Engl J Med. 2008 Mar 20;358(12):1250-
61. 
 24. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. 
CA Cancer J Clin. 2011 Feb 4. [Epub ahead of print].  
 25. Stephenson RA, Mori M, Hsieh YC, Beer TM, Stanford JL, Gilliland FD, Hoffman 
RM, Potosky AL. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, 
Epi[INVESTIGATOR_623], and End Results Prostate Cancer Outcomes Study. J Urol. 2005 Aug;174(2):646- 50; discussion 650.  
 26. Jarow JP, Nana- Sinkam P, Sabbagh M, Eskew A. Outcome analysis  of goal 
directed therapy for impotence. J Urol. 1996 May;155(5):1609- 12. 
 27. Mulhall JP, Ahmed A, Branch J, Parker M. Serial assessment of efficacy and 
satisfaction profiles following penile prosthesis surgery. J Urol. 2003 Apr;169(4):1429-33. 
 28. Rajpurkar A, Dhabuwala CB. Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice. J Urol. 2003 Jul;170(1):159- 63. 
 29. Bae JH, Song PH, Kim HT, Moon KH. Assessment of erectile and ejaculatory 
function after penile prosthesis implantation. Korean J Urol. 2010 Mar;51(3):202- 7. 
Epub 2010 Mar 19.  
 30. Montorsi F, Rigatti P, Carmignani G, Corbu C, Campo B, Ordesi G, Breda G, 
Silvestre P, Giammusso B, Morgia G, Graziottin A. AMS three -pi[INVESTIGATOR_230844]: a long -term multi -institutional study in 200 consecutive patients. 
Eur Urol. 2000 Jan;37(1):50- 5. 
 31. Carson CC, Mulcahy JJ, Govier FE. Efficacy,  safety and patient satisfaction 
outcomes of the AMS 700CX inflatable penile prosthesis: results of a long -term 
multicenter study. AMS 700CX Study Group. J Urol. 2000; Aug;164(2):376- 80. 
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 43 of 55 32. Dhar NB, Angermeier KW, Montague DK. Long -term mechanical reliability of AMS 
700CX/CXM inflatable penile prosthesis. J Urol. 2006 Dec;176(6 Pt 1):2599- 601; 
discussion 2601.  
 
33. Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of, and 
patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol. 2001 Sep;166(3):932- 7. 
 34. Lux M, Reyes -Vallejo L, Morgentaler A, Levine LA. Outcomes and satisfaction rates 
for the redesigned 2- pi[INVESTIGATOR_230845]. J Urol. 2007 Jan;177(1):262- 6. 
 35. Natali A, Olianas R, Fisch M. Penile implantation in Europe: successes and 
complications with 253 implants in Italy and [LOCATION_013]. J Sex Med. 2008 Jun;5(6):1503-12. Epub 2008 Apr 10.  
 36. Levine LA, Benson J, Hoover C. Inflatable penile prosthesis placement in men with 
Peyronie' s disease and drug -resistant erectile dysfunction: A single- center study. J Sex 
Med. 2010 Nov;7(11):3775- 83. 
 37. Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA. 2005 Jun 
1;293(21):2648- 53. 
 38. Montorsi F, Adaikan G, Becher E, Giul iano F, Khoury S, Lue TF, Sharlip I, Althof 
SE, Andersson KE, Brock G, Broderick G, Burnett A, Buvat J, Dean J, Donatucci C, Eardley I, Fugl -Meyer KS, Goldstein I, Hackett G, Hatzichristou D, Hellstrom W, Incrocci 
L, Jackson G, Kadioglu A, Levine L, Lewis RW, Maggi M, McCabe M, McMahon CG, Montague D, Montorsi P, Mulhall J, Pfaus J, Porst H, Ralph D, Rosen R, Rowland D, Sadeghi -Nejad H, Shabsigh R, Stief C, Vardi Y, Wallen K, Wasserman M. Summary of 
the recommendations on sexual dysfunctions in men. J Sex M ed. 2010 Nov;7(11):3572-
88. 
 39. Kaminetsky JC, Depko AJ, Ströberg P, Buvat J, Tseng LJ, Stecher VJ. In men with 
erectile dysfunction, satisfaction with quality of erections correlates with erection hardness, treatment satisfaction, and emotional well -being. J Sex Med. 2009 
Mar;6(3):800- 8. Epub [ADDRESS_278092] H, Vardi Y, Akkus E, Melman A, Park NC, Seftel AD, Teloken C, Wyllie M. 
Standards for clinical trials in male sexual dysfunctions. J Sex Med. 2010 Jan;7(1 Pt 2):414- 44. 
 41. Hellstrom WJ, Monta gue DK, Moncada I, Carson C, Minhas S, Faria G, 
Krishnamurti S. Implants, mechanical devices, and vascular surgery for erectile dysfunction. J Sex Med. 2010 Jan;7(1 Pt 2):501- 23. 
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 44 of 55 42. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, 
Milbank AJ, Nehra A, Sharlip ID; Erectile Dysfunction Guideline Update Panel. Chapter 
1: The management of erectile dysfunction: an AUA update. J Urol. 2005 
Jul;174(1):230- 9. 
 43. Mulhall J, Althof S, Brock G, Goldstein I, Jünemann K -P, Kirby M. Erectile 
dysfunction: Monitoring response to treatment in clinical practice— recommendations of 
an international consensus panel. J Sex Med 2007;4:448– 64. 
 44. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5- year 
review of research and clinical experience. Int J Impot Res. 2005 Jul -Aug;17(4):307- 19. 
 45. Köhler TS, Pedro R, Hendlin K, Utz W, Ugarte R, Reddy P, Makhlouf A, Ryndin I, 
Canales BK, Weiland D, Nakib N, Ramani A, Anderson JK, Monga M. A pi[INVESTIGATOR_230846]. BJU Int. [ADDRESS_278093];100(4):858- 62. 
 46. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and 
evaluation of an abridged, 5- item version of the International Index of Erectile Function 
(IIEF -5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999 
Dec;11(6):319- 26. 
 47. Gorbatiy V, Westney OL, Romero C, Wang R. Outcomes of simultaneous 
placement of an inflatable penile prosthesis and a male urethral sling through a single perineal incision. J Sex Med. 2010 Feb;7(2 Pt 1):832- 8. Epub 2009 Sep 29.  
 48. Bauer RM, Soljanik I, Füllhase C, Karl A, Becker A, Stief CG, Gozzi C. Mid -term 
results for the retroluminar transobturator sling suspension for stress urinary incontinence after prostatectomy. BJU Int. 2010 Sep 30.  
 49. Imbimbo C, Creta M, Gacci M, Simonato A, Gontero P, de Cobelli O, Briganti A,  
Fulcoli V, Martorana G, Nicita G, Mirone V, Carmignani G. Patients' Desire to Preserve Sexual Activity and Final Decision for a Nerve- Sparing Approach: Results from the 
MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and  
Research) Study. J Sex Med. 2011 Feb 16.  
 50. Mulhall JP, Goldstein I, Bushmakin AG, Cappelleri JC, Hvidsten K. Validation of the 
erection hardness score.  J Sex Med. 2007 Nov;4(6):1626- 34. Epub 2007 Sep 21.  
 51. King R, Juenemann KP, Levinson IP, Stecher VJ, Creanga DL. Correlations 
between increased erection hardness and improvements in emotional well -being and 
satisfaction outcomes in men treated with sildenafil citrate for erectile dysfunction. Int J Impot Res. 2007 Jul -Aug;19(4):398- 406. Epub 2007 Mar 15.  
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 45 of 55 52. Goldstein I, Mulhall JP, Bushmakin AG, Cappelleri JC, Hvidsten K, Symonds T: The 
Erection Hardness Score and its relationship to successful sexual  intercourse. J Sex 
Med 2008; Epub ahead of print.  
 
53. Hsiao W, Bennett N, Guhring P, Narus J, Mulhall JP. Satisfaction profiles in men 
using intracavernosal injection therapy. J Sex Med. 2011 Feb;8(2):512- 7. 
 54. Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., Leach, G. E. et al: 
Quality -of-life outcomes in men treated for localized prostate cancer. JAMA, 273: 129, 
1995.  
 55. Lepor H, Kaci L. The impact of open radical retropubic prostatectomy on continence 
and lower urinary tract symptoms: a prospective assessment using validated self -
administered outcome instruments. J Urol. 2004 Mar;171(3):1216- 9. 
 56. Reynolds WS, Shikanov SA, Katz MH, Zagaja GP, Shalhav AL, Zorn KC. Analysis 
of continence rates following robot -assisted radical prostatect omy: strict leak -free and 
pad-free continence. Urology. 2010 Feb;75(2):431- 6. Epub [ADDRESS_278094] F, McCormack M, Saad F, Karakiewicz 
PI. Validation of prostate cancer index and SF -12 short forms. Can J Urol. 2005 
Dec;12(6):2873- 9. 
 58. Anger JT, Maliski SL, Krupski TL, Kwan L, Gore JL, Fink A, Connor SE, Orecklin 
JR, Litwin MS. Outcomes in men denied access to a [LOCATION_004] public assistance program for prostate cancer. Public Health Rep. 2007 Mar -Apr;122(2):217- 23. 
 59. Litwin MS, McGuican KA, Shpall AI, Dhanani N (1999) Recovery of health related 
QoL in the year after radical prostatectomy: early experience. J Urol 161: 515.  
 60. Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, 
Hoffm an RM, Stephenson RA, Potosky AL, Stanford JL. 5- year urinary and sexual 
outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol. 2005 May;173(5):1701- 5. 
 61. Rogers CG, Su LM, Link RE, Sullivan W, Wagner A, Pavlovich CP. Age stratified 
functional outcomes after laparoscopic radical prostatectomy. J Urol. 2006 Dec;176(6 Pt 1):2448- 52. 
 62. Cornu JN, Sèbe P, Ciofu C, Peyrat L, Cussenot O, Haab F. Mid- term evaluation of 
the transobturator male sling for post -prostatectomy  incontinence: focus on prognostic 
factors. BJU Int. [ADDRESS_278095] 18.  
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 46 of 55 63. Christine B, Knoll LD. Treatment of recurrent urinary incontinence after artificial 
urinary sphincter placement using the AdVance male sling. Urology. 2010 
Dec;76(6):1321- 4. Epub 2010 A ug 14.  
 64. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, 
Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992 Nov;148(5):1549- 57; discussion 1564.  
 65. Deliveliotis C, Liakouras C, Delis A, Skolarikos A, Varkarakis J, Protogerou V. 
Prostate operations: long -term effects on sexual and urinary function and quality of life. 
Comparison with an age- matched control population. Urol Res. 2004 Aug;32(4):283- 9. 
Epub 2004 Mar 31.  
 66. Shikanov S, Desai V, Razmaria A, Zagaja GP, Shalhav AL. Robotic radical 
prostatectomy for elderly patients: probability of achieving continence and potency 1 year after surgery. J Urol. 2010 May;183(5):1803- 7. Epub 2010 Mar 17.  
 67. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health- related quality of life in men with prostate cancer. Urology. 2000 
Dec 20;56(6):899- 905. 
 68. Ware J Jr, Kosinski M, Keller SD. A 12-item short -form health survey: construction 
of scales and preliminary tests of reliability and validity. Med Care 1996;34:220- 33. 
 69. Ware J Jr, Kosinski M, Kel ler SD. SF-12: how to score the SF -12 physical and 
mental health summary scales. [LOCATION_011]: The Health Institute, New England Medical Center; 1995.  
 70. Clark JA, Inui TS, Silliman RA, Bokhour BG, Krasnow SH, Robinson RA, Spaulding 
M, Talcott JA. Patients' pe rceptions of quality of life after treatment for early prostate 
cancer. J Clin Oncol. [ADDRESS_278096] 15;21(20):3777- 84. 
 71. Liu H, Hays RD, Adams JL, Chen WP, Tisnado D, Mangione CM, Damberg CL, 
Kahn KL. Imputation of SF -12 health scores for respondents with pa rtially missing data. 
Health Serv Res. 2005 Jun;40(3):905- 21. 
 72. International Committee of Medical Journal Editors (ICMJE).  Uniform Requirements 
for Manuscripts Submitted to Biomedical Journals:  Ethical Considerations in the Conduct and Reporting of Research: Authorship and Contributorship.  Available at:  http://www.icmje.org/ethical_1author.html.   Accessed 10 May 2010.  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 47 of 55  
APPENDIX 1  - QUESTIONNAIRES  
International Index of Erectile Function-5 / Sexual Health Inventory for Men 
(IIEF-5/SHIM)  
 
The 5  specific questions comprising the IIEF -5/SHIM  are shown below.  Each question 
is preceded by [CONTACT_144845], “Over the past 6 months ,”: 
 
1. How do you rate your confidence that you could get and keep an erection ? 
[ADDRESS_278097] enough for penetration?  
[ADDRESS_278098] never/never  
2 - A few times (much less than half the time)  
3 - Sometimes (about half the time)  
[ADDRESS_278099] times (much more than half the time)  
[ADDRESS_278100] always/always  
3. During sexual intercourse, how often were you able to maintain your erection 
after you had penetrated (entered) your partner? 
[ADDRESS_278101] never/never  
2 - A few times (much less than half the time)  
3 - Sometimes (about half the time)  
[ADDRESS_278102] times (much more than half the time)  
[ADDRESS_278103] always/always  
4. During sexual intercourse, how difficult was it to maintain your erection to 
complet ion of  intercourse?  
1 - Extremely difficult  
2 - Very difficult  
3 - Difficult  
4 - Slightly difficult  
5 - Not difficult  
5. When you attempted sexual intercourse, how often was it satisfactory for you? 
[ADDRESS_278104] never/never  
2 - A few times (much less than half the time)  
3 - Sometimes (about half the time)  
[ADDRESS_278105] times (much more than half the time)  
[ADDRESS_278106] always/always  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 48 of 55 EHS Erection Hardness Questionnaire 
The specific question comprising the EHS is  shown below . 
 
EHS: “How would you rate the hardness of your erection?”  
0: Penis does not enlarge.  
1: Penis is larger but not hard.  
2: Pen is is hard but not hard enough for penetration.  
3: Penis is hard enough for penetration but not completely hard.  
4: Penis is completely hard and fully rigid.  
 
SF-12 Health -related Quality of Life (HRQOL) Questionnaire 
 
The 7  specific questions comprising the SF -12 are shown below.   
 
1. In general, would you say your health is:  
1 - Excellent  
2 - Very good  
3 - Good 
4 - Fair 
5 - Poor  
 
2. The following questions are about activities you might do during a typi[INVESTIGATOR_5707]. 
Does your health now limit you in these activities? If so, how much?  
 Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling or playing golf  
1 – Yes, limited a lot  
2 – Yes, limited a little  
3 – No, not limited at all  
 Climbing several flights of stairs  
 1 – Yes, limited a l ot 
2 – Yes, limited a little  
3 – No, not limited at all  
 
 3. During the past [ADDRESS_278107] you had any of the 
following problems with your work or other regular daily activities as a result of your physical health  
   Accomplished less t han you would like 
1 – All of the time  
2 – Most of the time 
3 – Some of the time  
4 – A little of the time  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 49 of 55 5 – None of the time  
 
Were limited in the kind of work or other activities  
1 – All of the time  
2 – Most of the time 
3 – Some of the time  
4 – A little of the time  
5 – None of the time  
 
4. During the past [ADDRESS_278108] you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious)?  
 
 Accomplished less than you would like 
1 – All of the time  
2 – Most of the time 
3 – Some of the time  
4 – A little of the time  
5 – None of the time  
 
Did work or other activities less carefully than usual  
1 – All of the time  
2 – Most of the time 
3 – Some of th e time  
4 – A little of the time  
5 – None of the time  
 5. During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and housework)? 
1- Not at all  
2 – A little bit  
3 – Moderately  
4 – Quite a bit  
5 – Extremely  
 6. These questions are about how you feel and how things have been with you during the past [ADDRESS_278109] 4 weeks … 
 
Have you felt calm and peaceful?  
1 – All of the time  
2 – Most of the time 
3 – Some of the time  
4 – A little of the time  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 50 of 55 5 – None of the time  
 
Did you have a lot of energy?  
1 – All of the time  
2 – Most of the time 
3 – Some of the time  
4 – A little of the  time 
5 – None of the time  
 
Have you felt downhearted and depressed?  
1 – All of the time  
2 – Most of the time 
3 – Some of the time  
4 – A little of the time  
5 – None of the time  
 
7. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting friends, 
relatives, etc.)?  
1 – All of the time  
2 – Most of the time 
3 – Some of the time  
4 – A little of the time  
5 – None of the time  
 
American Urological Association – Symptom Index (AUA -SI)  
The [ADDRESS_278110] you had a sensation of not emptying your bladder completely after you finished urinating? 
 0 – Not at all  
1 – Less than 1 time in 5  
2 – Less than half the time  
3 – About half the time  
4 – More than half the time  
5 – Almost always  
 
Over the past month, how often have you had to urinate again less than two 
hours after you finished urinating? 
0 – Not at all  
1 – Less than 1 time in 5  
2 – Less than half  the time  
3 – About half the time  
4 – More than half the time  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 51 of 55 5 – Almost always  
 
Over the past month, how often have you found you stopped and started again 
several times when you urinated?  
0 – Not at all  
1 – Less than 1 time in 5  
2 – Less than half the ti me 
3 – About half the time  
4 – More than half the time  
5 – Almost always  
 
Over the past month, how often have you found it difficult to postpone urination?  
0 – Not at all  
1 – Less than 1 time in 5  
2 – Less than half the time  
3 – About half the time  
4 – More than half the time  
5 – Almost always  
 
Over the past month, how often have you had a weak urinary stream? 
0 – Not at all  
1 – Less than 1 time in 5  
2 – Less than half the time  
3 – About half the time  
4 – More than half the time  
5 – Almost always  
 
Over the past month, how often have you had to push or strain to begin 
urination?  
0 – Not at all  
1 – Less than 1 time in 5  
2 – Less than half the time  
3 – About half the time  
4 – More than half the time  
5 – Almost always  
 
Over the past month, how many times did you  most typi[INVESTIGATOR_230847]?  
0 – None 
1 – 1 time  
2 – 2 times  
3 – 3 times  
4 – 4 times  
5 – 5 times  
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, 2016 Page 52 of 55 UCLA-Prostate Cancer Index (UCLA-PCI) Questionnaire 
The [ADDRESS_278111] 4 weeks?  
1. Your level of sexual desire? 
1 - Very poor  
2 - Poor   
3 – Fair 
4 – Good  
[ADDRESS_278112] an erection?  
1 - Very poor  
2 – Poor  
3 – Fair 
4 – Good  
5 - Very Good  
3. Your ability to reach orgasm (climax)? 
1- Very poor  
2- Poor  
3 – Fair 
4- Good 
5 - Very Good  
4. How would you describe the usual QUALITY of your erection?  
1 - None at all  
2 - Not firm  enough for any sexual activity  
3 - Firm enough for  masturbation and foreplay only  
4 - Firm enough for intercourse  
5. How would you describe the FREQUENCY of your erections?  
[ADDRESS_278113] you awakened in the morning or night with an erection?  
1 –Never  
2 - Seldom (less than 25% of the time)  
3 - Not often (less than half the time)  
4 - Often (more than half the time)  
5 - Very often (more than 75% of the time)  
7. During the last [ADDRESS_278114] vaginal or anal intercourse?  
1 –No 
2 - Yes, Once  
3 - Yes, More than onc e 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278115] 4 
weeks? 
1 - Very poor  
2 – Poor  
3 - Fair  
4 – Good  
[ADDRESS_278116] 4 weeks?  
[ADDRESS_278117] you leaked urine?  
[ADDRESS_278118] 4 
weeks? 
[ADDRESS_278119] 4 weeks?  
1- [ADDRESS_278120] 4 weeks?  
 
Drippi[INVESTIGATOR_230848]  
0 - No problem  
1 - Very small probl em 
2 - Small problem  
3 - Moderate problem  
4 - Big problem  
Urine leakage interfering with your sexual activity  
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278121] 4 weeks?  
1- No problem  
2-  Very small problem  
3-  Small problem  
4-  Moderate problem  
5-  Big problem  
 Bowel Function  
1. How often have you had rectal urgency (felt like I had to pass stool, but did not) during the last 4 weeks?  
[ADDRESS_278122] you had stools (bowel movements) that were loose or liquid (no form, watery, mushy) during the last 4 weeks?  
[ADDRESS_278123] 4 weeks? 
1- Severe distress  
2-  Moderate distress  
3-  Little distress  
4-  No distress  
4. How often have you had crampy pain in your abdomen or pelvis during the last 4 weeks?  
1- Several times a day  
2-  About once a day  
3-  Several times a week  
4-  About once a week  
5-  About once this month  
6-  Rarely or never  
 
D009530  
Rev03  
 
 
BSC Study: U0552 March 17, [ADDRESS_278124] 4 weeks?  
1- No problem  
2-  Very small problem  
3- Small problem  
4-  Moderate problem  
5-  Big problem  